26th April 2017

EFPIA: A Strong EU IP Framework Guarantees Future Innovation For Patients

Life expectancy in Europe has increased by nearly a decade over the last 50 years; 2 out of 3 people diagnosed with cancer live at least 5 years; HIV has been transformed from a death sentence to a manageable disease; and over 90% of Hepatitis C sufferers can be cured with a 12-week course of medicine. We are in a phase of exciting, ground-breaking science that has the potential to open up new treatment options for patients in disease areas we thought were previously untreatable, EFPIA, European Federation of Pharmaceutical Industries and Associations, comments on the occasion of the World IP Day.

EFPIA President, Joe Jimenez: "The IP system we have today is by no means perfect, but it works. With more than 7,000 medicines in development, the pharmaceutical industry is working hard to deliver new, more effective solutions to patients in need. There remains great unmet need across the globe. We still don’t have effective treatments for debilitating diseases such as Alzheimer’s and many infectious diseases are still too often fatal. Innovation is our best means of tackling those challenges and IP the most effective tool we have to unlock new solutions". Read full article.

Members of the American Chamber of Commerce in the Czech Republic